Charles G. Fisher

An osteogenic microenvironment improves response during denosumab treatment in giant cell tumors of bone in the spine

Giant cell tumors of bone are benign but locally aggressive tumors. Typically diagnosed in individuals between the ages of 20 and 40 years, these tumors cause significant amounts of pain, and morbidity. Giant cell tumors of bone can be treated with an increased dosing regimen of denosumab, a monoclonal antibody tha...